Other Species / Isoforms
  NHE1 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
S5-p
___MVLRsGICGLsP
0 1
NHE1 (human) ___MVLRsGICGLsP S5-p
NHE1 (mouse) __MMLRWSGVWGFHP S6
NHE1 (rat) __MMLRWSGIWGLYP S6
S11-p
RsGICGLsPHRIFPs
0 1
NHE1 (human) RsGICGLsPHRIFPs S11-p
NHE1 (mouse) WSGVWGFHPPRIFPS H12
NHE1 (rat) WSGIWGLYPPRIFPS Y12
S18-p
sPHRIFPsLLVVVAL
0 1
NHE1 (human) sPHRIFPsLLVVVAL S18-p
NHE1 (mouse) HPPRIFPSLLVVVAL S19
NHE1 (rat) YPPRIFPSLLVVVAL S19
T42-p
HGLQLSPtASTIRSS
0 1
NHE1 (human) HGLQLSPtASTIRSS T42-p
NHE1 (mouse) HGLQHSPTASTIRGS T43
NHE1 (rat) HGLQLNPTASTIRGS T43
Y96-p
FPVLGIDyTHVRTPF
0 1
NHE1 (human) FPVLGIDyTHVRTPF Y96-p
NHE1 (mouse) FPVLDIDYPHVRTPF Y100
NHE1 (rat) FPVLDIDYLHVRTPF Y100
S158-p
ETPPFLQsDVFFLFL
0 1
NHE1 (human) ETPPFLQsDVFFLFL S158-p
NHE1 (mouse) ETPPFLQSDVFFLFL S162
NHE1 (rat) ETPPFLQSDVFFLFL S162
K559-ub
RFNKKYVkkCLIAGE
0 1
NHE1 (human) RFNKKYVkkCLIAGE K559-ub
NHE1 (mouse) RFNKKYVKKCLIAGE K563
NHE1 (rat) RFNKKYVKKCLIAGE K563
K560-ub
FNKKYVkkCLIAGER
0 1
NHE1 (human) FNKKYVkkCLIAGER K560-ub
NHE1 (mouse) FNKKYVKKCLIAGER K564
NHE1 (rat) FNKKYVKKCLIAGER K564
K569
LIAGERSKEPQLIAF
0 1
NHE1 (human) LIAGERSKEPQLIAF K569
NHE1 (mouse) LIAGERSkEPQLIAF K573-ub
NHE1 (rat) LIAGERSKEPQLIAF K573
Y577-p
EPQLIAFyHKMEMkQ
0 36
NHE1 (human) EPQLIAFyHKMEMkQ Y577-p
NHE1 (mouse) EPQLIAFyHKMEMKQ Y581-p
NHE1 (rat) EPQLIAFYHKMEMKQ Y581
K583-ub
FyHKMEMkQAIELVE
0 1
NHE1 (human) FyHKMEMkQAIELVE K583-ub
NHE1 (mouse) FyHKMEMKQAIELVE K587
NHE1 (rat) FYHKMEMKQAIELVE K587
S599-p
GGMGKIPsAVstVsM
0 21
NHE1 (human) GGMGKIPsAVstVsM S599-p
NHE1 (mouse) GGMGKIPsAVstVsM S603-p
NHE1 (rat) GGMGKIPsAVSTVsM S603-p
S602-p
GKIPsAVstVsMQNI
0 20
NHE1 (human) GKIPsAVstVsMQNI S602-p
NHE1 (mouse) GKIPsAVstVsMQNI S606-p
NHE1 (rat) GKIPsAVSTVsMQNI S606
T603-p
KIPsAVstVsMQNIH
0 9
NHE1 (human) KIPsAVstVsMQNIH T603-p
NHE1 (mouse) KIPsAVstVsMQNIH T607-p
NHE1 (rat) KIPsAVSTVsMQNIH T607
S605-p
PsAVstVsMQNIHPk
0 30
NHE1 (human) PsAVstVsMQNIHPk S605-p
NHE1 (mouse) PsAVstVsMQNIHPk S609-p
NHE1 (rat) PsAVSTVsMQNIHPK S609-p
K612-ub
sMQNIHPkSLPsERI
0 4
NHE1 (human) sMQNIHPkSLPsERI K612-ub
NHE1 (mouse) sMQNIHPkAVTSDRI K616-ub
NHE1 (rat) sMQNIHPKSAASERI K616
S616-p
IHPkSLPsERILPAL
0 1
NHE1 (human) IHPkSLPsERILPAL S616-p
NHE1 (mouse) IHPkAVTSDRILPAL S620
NHE1 (rat) IHPKSAASERILPAL S620
S624-p
ERILPALskDKEEEI
0 3
NHE1 (human) ERILPALskDKEEEI S624-p
NHE1 (mouse) DRILPALsKDKEEEI S628-p
NHE1 (rat) ERILPALsKDKEEEI S628-p
K625-ub
RILPALskDKEEEIR
0 1
NHE1 (human) RILPALskDKEEEIR K625-ub
NHE1 (mouse) RILPALsKDKEEEIR K629
NHE1 (rat) RILPALsKDKEEEIR K629
N637
EIRKILRNNLQKTRQ
0 1
NHE1 (human) EIRKILRNNLQKTRQ N637
NHE1 (mouse) EIRKILRsNLQKTRQ S641-p
NHE1 (rat) EIRKILRSNLQKTRQ S641
S648-p
KTRQRLRsYNRHtLV
Upstream
Downstream
3 7
Effects on Modified Protein
  • activity, inhibited
  • molecular association, regulation
Kinase, in vitro:
  • Akt1 (human)
NHE1 (human) KTRQRLRsYNRHtLV S648-p
NHE1 (mouse) KTRQRLRSYNRHTLV S652
NHE1 (rat) KTRQRLRsYNRHTLV S652-p
T653-p
LRsYNRHtLVADPyE
Upstream
Downstream
2 4
Effects on Modified Protein
  • activity, induced
Effects on Biological Processes:
  • cell growth, altered
  • cell motility, induced
  • cytoskeletal reorganization
Kinase, in vitro:
  • BRAF (human)
  • ROCK1 (human)
  • ROCK2 (human)
Putative in vivo kinases:
  • BRAF (human)
Treatment
  • sorafenib
NHE1 (human) LRsYNRHtLVADPyE T653-p
NHE1 (mouse) LRSYNRHTLVADPYE T657
NHE1 (rat) LRsYNRHTLVADPYE T657
Y659-p
HtLVADPyEEAWNQM
Upstream
0 54
Treatment
  • Su11274
NHE1 (human) HtLVADPyEEAWNQM Y659-p
NHE1 (mouse) HTLVADPYEEAWNQM Y663
NHE1 (rat) HTLVADPYEEAWNQM Y663
Y683-p
LEQKINNyLtVPAHK
Upstream
0 126
Treatment
  • Su11274
NHE1 (human) LEQKINNyLtVPAHK Y683-p
NHE1 (mouse) LEQKITNyLtVPAHK Y687-p
NHE1 (rat) LEQKITNYLTVPAHK Y687
T685-p
QKINNyLtVPAHKLD
0 12
NHE1 (human) QKINNyLtVPAHKLD T685-p
NHE1 (mouse) QKITNyLtVPAHKLD T689-p
NHE1 (rat) QKITNYLTVPAHKLD T689
S693-p
VPAHKLDsPtMsRAR
Upstream
Downstream
1 212
Effects on Modified Protein
  • protein conformation
  • protein stabilization
Kinase, in vitro:
  • ERK2 (human)
NHE1 (human) VPAHKLDsPtMsRAR S693-p
NHE1 (mouse) VPAHKLDsPtLsRAR S697-p
NHE1 (rat) VPAHKLDsPTMsRAR S697-p
T695-p
AHKLDsPtMsRARIG
0 26
NHE1 (human) AHKLDsPtMsRARIG T695-p
NHE1 (mouse) AHKLDsPtLsRARIG T699-p
NHE1 (rat) AHKLDsPTMsRARIG T699
S697-p
KLDsPtMsRARIGsD
0 21
NHE1 (human) KLDsPtMsRARIGsD S697-p
NHE1 (mouse) KLDsPtLsRARIGsD S701-p
NHE1 (rat) KLDsPTMsRARIGsD S701-p
S703-p
MsRARIGsDPLAyEP
Upstream
Downstream
9 267
Effects on Modified Protein
  • activity, induced
Effects on Biological Processes:
  • cell growth, altered
  • cell growth, induced
  • cell motility, induced
  • cytoskeletal reorganization
  • transcription, altered
Kinase, in vitro:
  • Akt1 (human)
  • p90RSK (human)
Putative in vivo kinases:
  • p90RSK (human)
Treatment
  • anti-CD3
  • erlotinib
  • gefitinib
  • ischemia
  • PD98059
  • selumetinib
  • serum
  • Su11274
  • U0126
  • vemurafenib
NHE1 (human) MsRARIGsDPLAyEP S703-p
NHE1 (mouse) LsRARIGsDPLAyEP S707-p
NHE1 (rat) MsRARIGsDPLAYEP S707-p
Y708-p
IGsDPLAyEPKEDLP
0 21
NHE1 (human) IGsDPLAyEPKEDLP Y708-p
NHE1 (mouse) IGsDPLAyEPKADLP Y712-p
NHE1 (rat) IGsDPLAYEPKADLP Y712
T718-p
KEDLPVItIDPAsPQ
Upstream
2 3
Kinase, in vitro:
  • P38A (human)
NHE1 (human) KEDLPVItIDPAsPQ T718-p
NHE1 (mouse) KADLPVItIDPAsPQ T722-p
NHE1 (rat) KADLPVITIDPAsPQ T722
S723-p
VItIDPAsPQsPEsV
Upstream
2 19
Kinase, in vitro:
  • ERK2 (human)
  • P38A (human)
Treatment
  • ischemia
NHE1 (human) VItIDPAsPQsPEsV S723-p
NHE1 (mouse) VItIDPAsPQsPEsV S727-p
NHE1 (rat) VITIDPAsPQsPEsV S727-p
S726-p
IDPAsPQsPEsVDLV
Upstream
Downstream
3 14
Effects on Modified Protein
  • activity, induced
Effects on Biological Processes:
  • apoptosis, induced
Kinase, in vitro:
  • ERK2 (human)
  • P38A (human)
Putative in vivo kinases:
  • P38A (human)
Treatment
  • PD169316
NHE1 (human) IDPAsPQsPEsVDLV S726-p
NHE1 (mouse) IDPAsPQsPEsVDLV S730-p
NHE1 (rat) IDPAsPQsPEsVDLV S730-p
S729-p
AsPQsPEsVDLVNEE
Upstream
Downstream
3 9
Effects on Modified Protein
  • activity, induced
Effects on Biological Processes:
  • apoptosis, induced
Kinase, in vitro:
  • P38A (human)
Putative in vivo kinases:
  • P38A (human)
Treatment
  • PD169316
NHE1 (human) AsPQsPEsVDLVNEE S729-p
NHE1 (mouse) AsPQsPEsVDLVNEE S733-p
NHE1 (rat) AsPQsPEsVDLVNEE S733-p
K738-ub
DLVNEELkGKVLGLS
0 1
NHE1 (human) DLVNEELkGKVLGLS K738-ub
NHE1 (mouse) DLVNEELKGKVLGLN K742
NHE1 (rat) DLVNEELKGKVLGLK K742
K750-ub
GLSRDPAkVAEEDED
0 1
NHE1 (human) GLSRDPAkVAEEDED K750-ub
NHE1 (mouse) GLNRGPRVtPEEEEE V754
NHE1 (rat) GLKRGPRTTPEEEEE T754
V751
LSRDPAkVAEEDEDD
0 4
NHE1 (human) LSRDPAkVAEEDEDD V751
NHE1 (mouse) LNRGPRVtPEEEEED T755-p
NHE1 (rat) LKRGPRTTPEEEEED T755
S766-p
DGGIMMRsKETssPG
Upstream
Downstream
2 2
Effects on Modified Protein
  • activity, induced
Treatment
  • acidosis
NHE1 (human) DGGIMMRsKETssPG S766-p
NHE1 (mouse) DGIIMIRsKEPSsPG S771-p
NHE1 (rat) DGVIMIRsKEPssPG S771-p
S770-p
MMRsKETssPGtDDV
Upstream
Downstream
6 2
Effects on Modified Protein
  • activity, induced
  • protein conformation
  • protein stabilization
Kinase, in vitro:
  • ERK2 (human)
Treatment
  • acidosis
  • U0126
NHE1 (human) MMRsKETssPGtDDV S770-p
NHE1 (mouse) MIRsKEPSsPGtDDV S775
NHE1 (rat) MIRsKEPssPGTDDV S775-p
S771-p
MRsKETssPGtDDVF
Upstream
Downstream
6 4
Effects on Modified Protein
  • activity, induced
  • protein conformation
  • protein stabilization
Kinase, in vitro:
  • ERK2 (human)
Treatment
  • acidosis
  • U0126
NHE1 (human) MRsKETssPGtDDVF S771-p
NHE1 (mouse) IRsKEPSsPGtDDVF S776-p
NHE1 (rat) IRsKEPssPGTDDVF S776-p
T774-p
KETssPGtDDVFtPA
0 4
NHE1 (human) KETssPGtDDVFtPA T774-p
NHE1 (mouse) KEPSsPGtDDVFtPG T779-p
NHE1 (rat) KEPssPGTDDVFTPG T779
T779-p
PGtDDVFtPAPsDsP
Upstream
Downstream
1 7
Effects on Modified Protein
  • activity, induced
Kinase, in vitro:
  • ERK2 (human)
Treatment
  • acidosis
NHE1 (human) PGtDDVFtPAPsDsP T779-p
NHE1 (mouse) PGtDDVFtPGssDsP T784-p
NHE1 (rat) PGTDDVFTPGPSDsP T784
P782
DDVFtPAPsDsPssQ
0 1
NHE1 (human) DDVFtPAPsDsPssQ P782
NHE1 (mouse) DDVFtPGssDsPssQ S787-p
NHE1 (rat) DDVFTPGPSDsPGsQ P787
S783-p
DVFtPAPsDsPssQR
0 8
NHE1 (human) DVFtPAPsDsPssQR S783-p
NHE1 (mouse) DVFtPGssDsPssQR S788-p
NHE1 (rat) DVFTPGPSDsPGsQR S788
S785-p
FtPAPsDsPssQRIQ
Upstream
Downstream
2 76
Effects on Modified Protein
  • activity, induced
  • protein conformation
  • protein stabilization
Kinase, in vitro:
  • ERK2 (human)
Treatment
  • acidosis
NHE1 (human) FtPAPsDsPssQRIQ S785-p
NHE1 (mouse) FtPGssDsPssQRIQ S790-p
NHE1 (rat) FTPGPSDsPGsQRIQ S790-p
S787-p
PAPsDsPssQRIQRC
0 29
NHE1 (human) PAPsDsPssQRIQRC S787-p
NHE1 (mouse) PGssDsPssQRIQRC S792-p
NHE1 (rat) PGPSDsPGsQRIQRC G792
S788-p
APsDsPssQRIQRCL
0 29
NHE1 (human) APsDsPssQRIQRCL S788-p
NHE1 (mouse) GssDsPssQRIQRCL S793-p
NHE1 (rat) GPSDsPGsQRIQRCL S793-p
S796-p
QRIQRCLsDPGPHPE
Upstream
Downstream
3 69
Effects on Modified Protein
  • molecular association, regulation
Kinase, in vitro:
  • Akt1 (human)
Treatment
  • anti-CD3
  • ischemia
  • selumetinib
  • vemurafenib
NHE1 (human) QRIQRCLsDPGPHPE S796-p
NHE1 (mouse) QRIQRCLsDPGPHPE S801-p
NHE1 (rat) QRIQRCLsDPGPHPE S801-p